Literature DB >> 3011854

Comparison of detection of antibody to the acquired immune deficiency syndrome virus by enzyme immunoassay, immunofluorescence, and Western blot methods.

D Gallo, J L Diggs, G R Shell, P J Dailey, M N Hoffman, J L Riggs.   

Abstract

There was 100% agreement between enzyme immunoassay (EIA) (Abbott Laboratories), Western blot, and indirect immunofluorescence (IF) when these three methods were used to measure antibody to the acquired immune deficiency syndrome (AIDS) virus in sera from 142 high-risk individuals, indicating that IF was a sensitive alternative method for detecting antibody to this agent. Thirty-two (64%) of 50 EIA-positive plasma specimens from a blood bank and 6 (21%) of 28 EIA-positive sera from alternative testing sites were negative by IF. In addition, two EIA-negative sera from the latter group were positive by IF. Western blotting agreed with IF on those 40 specimens which gave discrepant results by EIA and IF. The IF method was determined to be equal to Western blotting in sensitivity and specificity for detection of AIDS antibody, and it was found to be useful for confirming positive EIA results, especially in specimens from individuals in low-risk groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011854      PMCID: PMC268791          DOI: 10.1128/jcm.23.6.1049-1051.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  6 in total

1.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

2.  Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.

Authors:  B Spire; D Dormont; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

3.  High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states.

Authors:  L S Kaminsky; T McHugh; D Stites; P Volberding; G Henle; W Henle; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors:  E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

5.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

6.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

  6 in total
  34 in total

1.  Evaluation of an indirect immunofluorescence assay for confirmation of human immunodeficiency virus type 1 antibody in U.S. blood donor sera.

Authors:  M T Sullivan; H Mucke; S D Kadey; C T Fang; A E Williams
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

2.  HIV-1 prevalence in selected Tijuana sub-populations.

Authors:  F Güereña-Burgueño; A S Benenson; J Sepúlveda-Amor
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

3.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

4.  Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study.

Authors:  G W Rutherford; A R Lifson; N A Hessol; W W Darrow; P M O'Malley; S P Buchbinder; J L Barnhart; T W Bodecker; L Cannon; L S Doll
Journal:  BMJ       Date:  1990-11-24

5.  Predicting human immunodeficiency virus type 1-positive sera by using two enzyme immunoassay kits in a parallel testing format.

Authors:  K Fonseca; C M Anand
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

6.  Humoral immune response to the bovine immunodeficiency-like virus in experimentally and naturally infected cattle.

Authors:  C A Whetstone; M J VanDerMaaten; J W Black
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  A western blot assay for the detection of antibodies to bovine immunodeficiency-like virus in experimentally inoculated cattle, sheep, and goats.

Authors:  C A Whetstone; M J VanDerMaaten; J M Miller
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.

Authors:  J Mahony; K Rosenthal; M Chernesky; S Castriciano; E Scheid; M Blajchman; D Harnish
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

9.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.

Authors:  B Forghani; J W Hurst; C S Chan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.